Background Secreted protein acidic and rich in cysteine (SPARC) is a matricellular protein that influences chemotherapy effectiveness and prognosis. The aim of this study was to investigate whether SPARC expression correlates with the postoperative survival of patients treated with surgical resection for biliary carcinoma. Methods SPARC expression in resected biliary carcinoma specimens was investigated immunohistochemically in 175 patients. The relationship between SPARC expression and prognosis after surgery was evaluated using univariate and multivariate analyses.
Introduction
Biliary tract carcinoma (BTC) is currently one of the most lethal human cancers. The incidence and mortality of biliary carcinoma have been increasing worldwide; 3700 and 18,000 patients per year die due to BTC in the USA and Japan, respectively.
1, 2 Surgical resection as a curative treatment has had unsatisfactory results. Overall 5-year survival rates after surgical resection for BTC have been reported to be 24.5∼33.1% in high volume centers. 3, 4 For decades, several perioperative therapeutic strategies have been attempted to improve the poor prognosis of patients with BTC. 5, 6 Specifically, gemcitabine has been recognized as a key drug in perioperative therapy for biliary carcinoma, as a few randomized control trials have demonstrated the survival benefit of gemcitabine-based chemotherapy for unresectable BTC. 7, 8 Therefore, the identification of predictive biomarkers for gemcitabine-based chemotherapy has been regarded as important for optimizing perioperative therapy for BTC.
Some studies have revealed that the behavior of carcinoma cells is influenced by not only the cancer cells themselves but also the surrounding stroma, [9] [10] [11] and dense peritumoral stroma may be associated with chemoresistance. Therefore, interest in biomarkers related to peritumoral stroma has increased recently. In particular, expression of secreted protein acidic and rich in cysteine (SPARC) has been reported to play an important role in several biological processes and may be a biomarker of activated fibroblasts. 12, 13 Indeed, SPARC expression was significantly associated with chemoresistance in pancreatic cancer treated with gemcitabine-based chemotherapy in a recent, large-scale study.
14 However, few studies have reported SPARC expression in BTC, and the prognostic role of SPARC in gemcitabine-based chemotherapy for BTC is still unclear. 15, 16 This study aimed to investigate the correlation between SPARC expression and survival of patients treated with surgical resection and subsequent adjuvant gemcitabinebased chemotherapy for BTC.
Patients and Methods

Study Design
This study analyzed data collected from an institutional database of patients with Union for International Cancer Control (UICC) stage II-IV 17 biliary carcinoma, including intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma, distal cholangiocarcinoma, gallbladder carcinoma, and ampullary carcinoma, who underwent surgical resection with curative intent (R0 or R1 resection) at the Department of Surgery, Hiroshima University Hospital, Hiroshima, Japan, from 1998 to 2014. Patients with postoperative mortality defined as deaths within 30 days after surgery were excluded from this study. Patients who had distant metastasis or peritoneal dissemination were also excluded from this study. However, patients with para-aortic lymph node metastasis, which was diagnosed only by postoperative pathological examination and not by preoperative imaging examinations, were included. Patients with intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma, or gallbladder carcinoma almost always underwent a wide variety of hepatectomy. Most patients with distal cholangiocarcinoma or ampullary carcinoma underwent pancreatoduodectomy with or without pylorus preservation. All specimens were examined by specialized pathologists, and each was classified as well differentiated, moderately differentiated, poorly differentiated, or undifferentiated according to the predominant pattern of histological differentiation. Tumor stage, lymph node metastasis, and final stage of BTC were graded using the UICC tumor-nodemetastasis (TMN) classification scheme (7th edition). 17 The study protocol and informed consent form followed the recommendations of the Declaration of Helsinki and were approved by the Institutional Review Board of Hiroshima University.
Adjuvant Gemcitabine-Based Chemotherapy
We have previously established adjuvant gemcitabine-based chemotherapy protocols to treat BTC in patients meeting institutional criteria. 18, 19 Eligibility criteria included Eastern Cooperative Oncology Group performance status 0-1, adequate bone marrow reserve (white blood cell count >3000/ mm 3 , platelet count >100,000/mm 3 , hemoglobin level >8 g/ dL), and adequate renal and liver function (serum creatinine concentration <1.5 mg/dL and total serum bilirubin concentration <3 mg/dL). Adjuvant gemcitabine-based chemotherapy, including gemcitabine alone (700 mg/m 2 administered intravenously biweekly) and gemcitabine + S-1 (700 mg/m 2 gemcitabine administered intravenously on day 1 and 60-100 mg/body administered orally for 7 consecutive days followed by a 1-week pause in chemotherapy), was administered beginning in 2002. Patients received 10 cycles of adjuvant chemotherapy every 2 weeks. No patient received radiation therapy during the perioperative period.
Immunohistochemistry
Immunohistochemistry was performed using the streptavidinperoxidase technique and the Dako EnVision+ System (Dako, Carpinteria, CA, USA). To evaluate SPARC expression, a monoclonal mouse antibody directed against SPARC (clone ON1-1; TaKaRa Bio, Inc., Otsu, Japan) was used as described previously. 20, 21 Briefly, 4-μm-thick tissue sections cut from formalin-fixed, paraffin-embedded tissue blocks were deparaffinized and rehydrated. After antigen retrieval by autoclaving (121°C, 10 min in 0.01 M citrate buffer), endogenous peroxide was blocked by immersing sections in methanol containing 3% hydrogen peroxide. Proteins were blocked by incubating sections in protein blocking solution (Dako). Next, sections were incubated with SPARC primary antibody (1:500 dilution) for 60 min at room temperature. Then, sections were incubated with labeled streptavidin-biotin polymerconjugated anti-mouse secondary antibodies (EnVision+, Dako) at room temperature for 60 min. Staining was visualized with 3,3′-diaminobenzidine (DAB), and sections were counterstained with Mayer's hematoxylin solutions. Sections were then dehydrated and mounted. Omission of primary antibody provided a negative control.
Immunohistochemical evaluation of cytoplasmic SPARC in biliary carcinoma cells and peripheral stromal SPARC expression was generated by two observers (K.T. and N.K.) who were blinded to clinical characteristics. When the results of SPARC expression differed between the two observers, the results were confirmed by consensus review. According to previous reports, 22, 23 staining of sections was evaluated based on the proportion of positively stained tumor cells and the intensity of staining. The proportion of positive cells with SPARC expression was evaluated as follows: 0 (≤5% positive cells), 1 (6-25%), 2 (26-50%), and 3 (≥51%). Staining intensity was scored using the following scale: 0 (no staining), 1 (weak staining, light yellow), 2 (moderate staining, yellow brown), and 3 (strong staining, brown). The staining index was calculated as the product of the staining intensity score and the proportion of positive cells. A staining index score ≥4 was considered high SPARC expression, whereas a staining index score ≤3 was considered low SPARC expression (Fig. 1) .
Survival
All patients were monitored regularly through blood tests and computed tomography every 3-6 months. For patients who died, survival time after surgery and the cause of death were recorded. The failure event for overall survival (OS) was defined as death from any cause. For surviving patients, postoperative survival times were recorded.
Statistical Analysis
Relationships between clinicopathological factors and SPARC expression were evaluated using the χ 2 test. The Kaplan-Meier method and the log-rank test were performed to examine differences in OS between two groups. Those factors found to be significant using univariate analysis were entered into multivariate analysis using a Cox proportional hazards model. A P value less than 0.05 was considered statistically significant. All statistical analyses were carried out using JMP statistical software (version 12, SAS Institute, Cary, NC, USA).
Results
Patient Demographics and Tumor Characteristics
This study analyzed data collected from an institutional database of 204 biliary carcinoma patients who underwent surgical resection with curative intent (R0 or R1 resection) at our institution from 1998 to 2014. Of these 204 patients, those excluded from this study were 25 patients with UICC stage I Fig. 1 Immunohistochemical analysis of secreted protein acidic and rich in cysteine (SPARC) expression in biliary carcinoma. a Strong cytoplasmic staining (×400). b Strong stromal staining (×400). c Absence of cytoplasmic and stromal staining (×400) tumors and 4 perihilar cholangiocarcinoma patients with postoperative mortality. The remaining 175 patients eligible for this study included 19 patients (11%) with intrahepatic cholangiocarcinoma, 62 patients (36%) with perihilar cholangiocarcinoma, 51 patients (29%) with distal cholangiocarcinoma, 25 patients (14%) with gallbladder carcinoma, and 18 patients (10%) with ampullary carcinoma. Based on the TNM system, 29 (16%) patients were diagnosed with stage II, 22 (13%) with stage IIA, 40 (23%) with stage IIB, 3 (2%) with stage III, 14 (8%) with stage IIIA, 27 (15%) with stage IIIB, 7 (4%) with stage IV, 23 (13%) with stage IVA, and 10 (6%) with stage IVB. A comparison of clinicopathological factors among the different locations of carcinoma is presented in Table 1 . Significant differences were found in R factor, pT factor, lymph node metastasis, and final stage.
Delivery of Postoperative Adjuvant Gemcitabine-Based Chemotherapy
Adjuvant gemcitabine-based chemotherapy was administered to 118 of the 175 eligible patients (67%). Of the 118 patients, 110 (93%) patients received adjuvant gemcitabine plus S-1 chemotherapy and 8 (7%) received gemcitabine alone. One hundred and five (89%) patients received 10 cycles of adjuvant gemcitabine-based chemotherapy. Of the other 13 (11%) patients who received less than 10 cycles of adjuvant gemcitabine-based chemotherapy, 7 (5%) had to shift to some other chemotherapies as a result of recurrent disease, 2 (2%) were due to side effects, 2 (2%) were patients' wish, and 2 (2%) were death of other diseases. There were no treatmentrelated deaths in any patients. In the 57 patients who did not receive adjuvant gemcitabine-based chemotherapy, 18 (32%) were patients who underwent surgery between 1998 and 2001, and 39 (68%) were patients who were not eligible to the criteria set and did not provide consent. In the comparison of characteristics of patients between with and without adjuvant gemcitabine-based chemotherapy, the age of patients was significantly different (P = 0.013, Table 2 ).
Relationship Between Clinicopathological Factors and SPARC Expression
Of the 175 patients, high cytoplasmic and stromal SPARC expressions were observed in 50 (29%) and 61 (35%) patients, respectively. The relationships of cytoplasmic and stromal SPARC expression with clinicopathological factors are summarized in Table 3 . No significant correlation was found between cytoplasmic SPARC expression and clinicopathological factors, whereas stromal SPARC expression was significantly associated with tumor location (P = 0.039). Table 4 . The use of adjuvant gemcitabine-based chemotherapy (P < 0.001), absence of lymph node metastasis (P < 0.001), and low stromal SPARC expression (P = 0.006) were significantly associated with longer OS (Fig. 2a) . In contrast, cytoplasmic SPARC expression did not affect OS (P = 0.942, Fig. 2b) . A multivariate proportional hazards regression model was fit using three variables identified as significant prognostic factors in the univariate analysis. Absence of postoperative adjuvant chemotherapy (P < 0. In the subset of 118 patients who received gemcitabinebased adjuvant chemotherapy, lymph node metastasis (P = 0.005) and high stromal SPARC expression (P = 0.003) were significantly associated with poor OS (Fig. 2c) . In the multivariate analysis of this same group, lymph node metastasis (P = 0.010; HR, 2.03; 95% CI, 1.18-3.59) and high stromal SPARC expression (P = 0.010; HR, 2.04; 95% CI, 1.19-3.46) were independent risk factors for poor OS. On the contrary, in the subset of 57 patients who did not receive gemcitabine-based adjuvant chemotherapy, stromal SPARC expression was not associated with OS according to the univariate analysis (P = 0.211, Fig. 2d ). Only lymph node metastasis (P = 0.008) was significantly associated with poor OS. In the multivariate analysis, lymph node metastasis was an independent risk factor for poor OS (P = 0.008; HR, 2.43; 95% CI, 1.25-4.89) ( Table 4) .
Discussion
These data revealed that high stromal SPARC expression was an independent predictor of poor overall survival, especially in the subgroup of patients treated with adjuvant gemcitabinebased chemotherapy. Stromal SPARC expression was not associated with pathological malignancy. Tumor location, which is only associated with stromal SPARC expression, was not associated with OS. These results suggest that high stromal SPARC expression contributes to the poor prognosis of biliary carcinoma patients due to its influence on resistance to adjuvant gemcitabine-based chemotherapy.
The prognoses of patients with intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma, distal cholangiocarcinoma, gallbladder carcinoma, and ampullary carcinoma have sometimes been reported separately because they have been regarded histologically different. However, the rarity of these biliary carcinomas makes it difficult to identify risk factors of poor prognosis and sensitivity to chemotherapy with statistical significance in separate investigations. Recent randomized control trials on chemotherapy for BTC also analyzed data of these five types of BTC together. 7, 8 The current study (21) demonstrated no significant difference in survival among the five types of biliary carcinoma. In addition, subanalyses by each tumor location showed that high stromal SPARC expression in any tumor location was likely to affect the poor prognosis though each did not reach statistical significance due to the small number of patients. These results indicated that stromal SPARC expression may have predictive value regardless of its tumor subtype. For these reasons, the data from these biliary carcinomas were merged into a single dataset in this study. Patients with UICC stage I tumors were excluded from this study to clarify the association between SPARC expression and sensitivity to chemotherapy; patients with stage I disease were expected to have good prognosis and often forewent adjuvant chemotherapy. SPARC is a member of the matricellular family of proteins, which are expressed and affect development, wound repair, and tissue remodeling. The reported functions of SPARC include modulating apoptosis, cell cycle progression, angiogenesis, matrix cell adhesion, proliferation, and migration. [24] [25] [26] These roles of SPARC in tumor tissue were likely related to carcinogenesis 12 and supposed to affect prognosis of patients with several types of cancer. 15, 16, 22, [27] [28] [29] [30] [31] In addition, the impact of SPARC on matrix cell proliferation and inhibition of angiogenesis is expected to be associated with sensitivity to SPARC secreted protein acidic and rich in cysteine, AGC adjuvant gemcitabine-based chemotherapy, MST median survival time, HR hazard ratio, CI confidence interval, UICC Union for International Cancer Control chemotherapy, as dense desmoplastic stroma could impede diffusion of cytotoxic drugs. 32, 33 These hypotheses were supported by a large-scale translational study in pancreatic cancer. The subanalysis of a controlled phase III trial investigating adjuvant gemcitabine therapy for pancreatic cancer (CONKO-001) by Sinn et al. demonstrated that high stromal SPARC expression could predict poor prognosis in patients receiving adjuvant gemcitabine chemotherapy but not in those without adjuvant therapy.
14 Their results indicated that stromal SPARC expression was a relevant prognostic marker for gemcitabine sensitivity. However, the prognostic impact of SPARC expression in BTC has been scarcely reported, 15, 16 and its predictive significance in gemcitabine-based chemotherapy is still unclear. To the best of our knowledge, this is the largest study (n = 175) investigating SPARC expression in resected BTC.
Similar to the current study, Nakashima et al. analyzed 110 cases of resectable BTC and found that high stromal SPARC expression was an independent risk factor for poor prognosis. 15 However, unlike the current analysis, the prognostic advantage of adjuvant chemotherapy was not demonstrated in their study. This discrepancy may be due to differences in the proportion of patients treated with adjuvant chemotherapy and/or different regimens of adjuvant chemotherapy. Nonetheless, their study and the current study revealed that the predictive significance of stromal SPARC expression was enhanced in the subgroup of patients treated with gemcitabine-based chemotherapy. Based on these results, Fig. 2 Overall survival curves for patients with biliary carcinoma after surgical resection. a All patients (n = 175) stratified by stromal secreted protein acidic and rich in cysteine (SPARC) expression (P = 0.006). b All patients (n = 175) stratified by cytoplasmic SPARC expression high stromal SPARC expression surrounding BTC cells was associated with resistance to gemcitabine-based chemotherapy and could predict prognosis of patients treated with surgical resection and subsequent adjuvant gemcitabine-based chemotherapy for BTC. In contrast, cytoplasmic SPARC expression did not affect prognosis in BTC in the current study. Indeed, only a few investigators have reported cytoplasmic SPARC expression, and the predictive significance of cytoplasmic SPARC expression in BTC has never been reported. Further investigation of the prognostic impact of cytoplasmic SPARC expression on BTC will be needed.
Development of new perioperative chemotherapeutic regimens for BTC will be needed to improve long-term survival, as the current postoperative prognosis remains unsatisfactory. In particular, research efforts have increasingly focused on understanding how peritumoral stroma influences the behavior of cancer cells and identifying treatments for peritumoral stroma. SPARC is possibly an important therapeutic target for peritumoral stroma. As an albumin sticker, SPARC is expected to enhance the intratumoral delivery of albumin-binding paclitaxel (nab-PTX). 13, 34 However, only a few reports on head and neck cancer and pancreatic cancer have demonstrated the value of SPARC expression in predicting response to nab-PTX, 35, 36 and treatments for stroma have not been established in BTC. As new chemotherapeutic regimens targeting peritumoral stroma are established in BTC, the evaluation of SPARC expression will become increasingly important.
The limitations of this study are the small number of analyzed cases and the study's retrospective nature. Consequently, patients with and without adjuvant gemcitabine-based chemotherapy were selected without randomization. In the comparison between with and without adjuvant gemcitabine-based chemotherapy, the age of patients was significantly different. However, the age of patients was not associated with prognosis and we think that it does not have much influence on the study of the relationship between SPARC expression and prognosis. Another limitation is the analysis of data that was merged into five subtypes of biliary carcinoma into a single dataset. Our results should be validated in further prospective randomized studies including larger number of patients with every subtype of biliary carcinoma.
In conclusion, high stromal SPARC expression was independently associated with poor prognosis of patients who received surgical resection and subsequent adjuvant gemcitabine-based chemotherapy. These results may support the use of SPARC expression level in clinical decision-making regarding gemcitabine-based chemotherapy.
